Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on September 29, 2015. The registrant is a Delaware corporation with its principal executive offices in Irvine, California. The report discloses a material definitive agreement entered into on the same date by ChromaDex, Inc., a wholly owned subsidiary of the registrant.
Key Financial Metrics and Agreement Terms
The filing details a "take or pay" agreement with W. R. Grace & Co. Conn. ("Grace") regarding the purchase of nicotinamide riboside chloride. Key financial terms include:
- Total Commitment: Approximately $6.1 million worth of product.
- Pricing Structure: Purchases are made at a set price per kilogram.
- Payment Obligation: If the full required amount is not purchased by December 31, 2015, ChromaDex must pay the difference based on the set price per kilogram.
- Payment Due Date: Payments for any shortfall are due by February 14, 2016.
- Shipping Terms: Quantities shipping after December 31, 2015, are payable net 60.
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
Material Changes and Unusual Items
The primary material change reported is the entry into the binding purchase agreement with Grace. This agreement creates a fixed financial liability for the $6.1 million commitment regardless of actual product uptake by the December 31, 2015 deadline. The filing notes that certain terms of the agreement will be filed under confidential treatment in the subsequent Form 10-Q.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or a discussion of general risks beyond the specific terms of the agreement. The primary contingency identified is the potential cash outflow required to cover any shortfall in product purchases by the end of 2015.
Investor Verification Checklist
- Verify the exact "Price per Kilogram" and total kilogram volume required to meet the $6.1 million commitment, as these specific figures are subject to confidential treatment.
- Review the upcoming Form 10-Q for the quarter ended October 3, 2015, for the full text of the agreement and any updated financial impact.
- Assess the company's current cash position to determine its ability to meet the February 14, 2016, payment deadline for any potential shortfall.
- Confirm the current inventory levels and sales velocity of nicotinamide riboside chloride to evaluate the likelihood of a shortfall payment.